Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease.
PR Newswire
BOSTON, June 25, 2026
Lead oral compounds demonstrated up to 25% body weight reduction with preferential fat loss, preserved lean mass, and broad metabolic improvements in DIO modelsBOSTON, June 25, 2026 /PRNewswire/ -- Mwyngil Therapeutics, a biotech company focused on developing innovative small molecule therapeutics for cardiometabolic disease, today announced positive in vivo proof-of-concept results from its GPR75 inverse agonist program, supporting the potential of GPR75 modulation as a differentiated therapeutic approach for obesity and cardiometabolic disease. In a 4-week, diet-induced obesity (DIO) mouse model, orally administered lead compounds produced dose-dependent body weight reduction of up to 25% versus vehicle while preserving lean mass across all tested doses. Importantly, weight reduction was accompanied by preferential loss of adipose tissue rather than muscle, with a 33–50% reduction in fat rate and up to 1.5-fold reduction in epididymal white adipose tissue (eWAT). Additional in vivo findings demonstrated broad metabolic improvements beyond body weight reduction, including:
